Considering Personalized Neoantigen Vaccine Approaches for Multiple Myeloma
Neoantigens may have the ability to provoke the immune system into recognizing and killing cancer cells in patients with multiple myeloma.
Multiple Myeloma
Multiple Myeloma Treatment Regimens
Find detailed drug treatment regimens for multiple myeloma, including primary therapy for both transplant candidates and non-transplant candidates.
MRD Status Assessed by Flow Cytometry Predicts Treatment Efficacy in Newly Diagnosed Multiple Myeloma
Next-generation flow cytometry involves assessments of both plasma cell-surface antigens and immunoglobulin light-chain expression.
Phase 2 Trial of Ibrutinib, Bortezomib, Dexamethasone Combination for R/R Multiple Myeloma Was Closed Early
Despite an overall response rate of 57%, this clinical trial was suspended due to safety concerns then closed early due to insufficient activity of the study drug combination.
Antibiotic Prophylaxis Shown to Reduce Infection Risk for Patients With Newly Diagnosed Multiple Myeloma
Prophylactic antibiotics trended toward reducing infection risk at 3 months if given in first 2 to 3 months after MM diagnosis; however, it had no effect on mortality rates.
Modified Bortezomib, Lenalidomide, Dexamethasone Induction Regimen Efficacious, Tolerable for Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma
A modified induction protocol (VRd lite) demonstrated high efficacy with better tolerability in patients with NDMM who are eligible for ASCT.
Tandem Transplant Strategies Associated With Higher Progression-Free Survival in Patients With Multiple Myeloma
This retrospective analysis compared auto-HSCT and allo-HSCT with tandem auto-HSCT and auto-allo-HSCT to determine which strategy provided better PFS and OS for patients with multiple myeloma.
A Case Report on a Rare Manifestation of Extramedullary Multiple Myeloma in an Elderly Man
This “Clinical Picture” describes a case of extramedullary multiple myeloma manifesting as a rapidly growing intraoral lesion.
Outpatient ASCT for Myeloma Found Safe, Effective With Proper Patient Selection
Only about one-third of patients required hospital admission.
Outcomes With Plerixafor Following Autologous Stem Cell Transplantation for Multiple Myeloma
The addition of plerixafor to treatment following transplantation may not enhance lymphocyte recovery in patients with multiple myeloma.
Next post in Multiple Myeloma
